Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07471763

Prospective Lifespan Cohort of Myocardial Infarction

This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.

The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.

The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 to 74 years

Diagnosed with stable angina, unstable angina, or acute myocardial infarction

For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized

Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction

Willing to participate and able to provide written informed consent

Able to complete baseline assessment, biospecimen collection, and long-term follow-up

Exclusion criteria

End-stage malignant tumor with expected survival of less than 1 year

Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)

Active autoimmune disease or long-term use of immunosuppressive agents

Pregnant or breastfeeding women

Inability to provide informed consent or severe cognitive impairment

Previous participation in another clinical study that may conflict with this project

Any other condition considered by the investigators to make participation inappropriate

Treatment and study plan

Primary outcomes

  1. Rate of all-cause mortality

    Time frame: From enrollment to the end of study follow-up, up to 5 years

Secondary outcomes

  1. Rate of cardiovascular death

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  2. Rate of recurrent myocardial infarction

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  3. Rate of readmission due to heart failure

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  4. Rate of target vessel or non-target vessel revascularization

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  5. Rate of stroke

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  6. Rate of definite or probable stent thrombosis

    Time frame: From enrollment to the end of study follow-up, up to 5 years

  7. Rate of severe bleeding

    Time frame: From enrollment to the end of study follow-up, up to 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Kaiyang Lin, PhD

CONTACT

[email protected]

+86 13559355708

Sponsors and collaborators

Lead sponsor

Fujian Provincial Hospital

Other

Registry information

Official study title

A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Mar 13, 2026
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.